Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TheraKine and Cell Care Therapeutics have entered into a licensing agreement to use TheraKine's injectable sustained release technology to enable Cell Care's stem cell therapies for diseases of the eye that commonly cause blindness.
Subscribe to our email newsletter
TheraKine has developed sustained release delivery technology platforms for injectable local delivery of biologic agents and live cells.
Cell Care uses stem cells to treat degenerative and inflammatory diseases of the eye.
Cell Care CEO Nicolas Sohl said: "It gives us all confidence to know that the effects of our proprietary regenerative therapies can be extended to many months in order to direct neuro-vascular repair and treat chronic inflammatory and degenerative ocular diseases over a clinically relevant period of time.
"We hope that we will soon be in human studies to help prevent otherwise incurable conditions that leave people blind or disabled."
TheraKine CEO Seth Yakatan said: "It is very exciting being part of the solution to enable many months of therapy with stem cells, using technologies we originally developed for antibodies, especially since stem cells show promise as the future of therapy for many difficult diseases."
The companies did not disclose the terms of the license.